Tibet Weixinkang Medicine Co Ltd (603676) - Total Assets
Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) holds total assets worth CN¥1.96 Billion CNY (≈ $287.49 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tibet Weixinkang Medicine Co Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 603676 market cap for the company's overall valuation and market capitalisation.
Tibet Weixinkang Medicine Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Tibet Weixinkang Medicine Co Ltd's total assets of CN¥1.96 Billion consist of 69.0% current assets and 31.0% non-current assets. Review Tibet Weixinkang Medicine Co Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.4% |
| Accounts Receivable | CN¥131.58 Million | 7.1% |
| Inventory | CN¥59.82 Million | 3.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥36.90 Million | 2.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Tibet Weixinkang Medicine Co Ltd (603676) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tibet Weixinkang Medicine Co Ltd's current assets represent 69.0% of total assets in 2025, an increase from 52.2% in 2013.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2025, down from 32.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 7.1% of total assets.
Tibet Weixinkang Medicine Co Ltd Competitors by Total Assets
Key competitors of Tibet Weixinkang Medicine Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
Tibet Weixinkang Medicine Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.62 | 3.84 | 2.34 |
| Quick Ratio | 3.45 | 3.71 | 2.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.01 Billion | CN¥991.84 Million | CN¥569.93 Million |
Tibet Weixinkang Medicine Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tibet Weixinkang Medicine Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.54 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 0.7% |
| Total Assets | CN¥1.87 Billion |
| Market Capitalization | $575.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tibet Weixinkang Medicine Co Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tibet Weixinkang Medicine Co Ltd's assets grew by 0.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tibet Weixinkang Medicine Co Ltd (2013–2025)
The table below shows the annual total assets of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.87 Billion ≈ $273.18 Million |
+0.71% |
| 2024-12-31 | CN¥1.85 Billion ≈ $271.25 Million |
+4.32% |
| 2023-12-31 | CN¥1.78 Billion ≈ $260.02 Million |
+6.74% |
| 2022-12-31 | CN¥1.66 Billion ≈ $243.60 Million |
+11.31% |
| 2021-12-31 | CN¥1.50 Billion ≈ $218.85 Million |
+9.96% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.02 Million |
+4.25% |
| 2019-12-31 | CN¥1.30 Billion ≈ $190.91 Million |
+5.64% |
| 2018-12-31 | CN¥1.23 Billion ≈ $180.72 Million |
+21.48% |
| 2017-12-31 | CN¥1.02 Billion ≈ $148.76 Million |
+84.05% |
| 2016-12-31 | CN¥552.36 Million ≈ $80.83 Million |
+8.57% |
| 2015-12-31 | CN¥508.75 Million ≈ $74.45 Million |
+40.01% |
| 2014-12-31 | CN¥363.37 Million ≈ $53.17 Million |
+17.48% |
| 2013-12-31 | CN¥309.30 Million ≈ $45.26 Million |
-- |
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium… Read more